OABI

4.6607.36%
JR

Jennifer R. Cochran

Independent Director

Dr. Jennifer R. Cochran, Ph.D., serves as Vice President for SLAC National Accelerator Laboratory and for Strategic Initiatives at Stanford University. At the university, she also serves as the Addie and Al Macovski Professor of Bioengineering and (by courtesy) of Chemical Engineering, Director of the Stanford/NIH Biotechnology predoctoral training program, and as a member of the Cancer Biology, Biophysics, and Immunology graduate programs. At Stanford, she also served as Senior Associate Vice Provost for Research from 2023 to 2026, as the Shriram Chair of the Bioengineering department from 2017 to 2022, as Professor since 2018, and as Assistant Professor. She joined the university in 2005 as one of the founding faculty members in its Bioengineering department. Dr. Cochran is Co-Founder of Red Tree Venture Capital, where she also serves as Chief Scientific Advisor and Scientific Advisory Board Chair since August 2020. She is also Co-Founder of TwoStep Therapeutics, Inc., Founder of Threefold Therapeutics, and Founder of Photinia Biosciences. She serves as an Independent Director at Revel Pharmaceuticals Inc., as an Independent Director at OmniAb, Inc. since November 1, 2022, and as a Director at Rondo Therapeutics, Inc. since June 2024. Dr. Cochran also serves on the Boards of Directors for Virsti Therapeutics, Inc., Trapeze Therapeutics, Inc., Syndeo Therapeutics, Excellergy Therapeutics, Kivu Bioscience, Biograph55, and Ebvio. Additionally, she is an Observer of Acrigen Biosciences, Inc. since 2023, an Observer of Tachyon Therapeutics, Inc. since 2023, and a Venture Partner at Lagunita Biosciences. Previously, she served as an Independent Director at Ligand Pharmaceuticals Incorporated from July 12, 2021 to November 2022. She is Co-Founder of Lagunita Biosciences and also served as its Chief Scientist from October 2015 to April 2020. She is Co-Founder of xCella Biosciences and also served as Director until 2020 and as President from 2015 to 2017. She is Founder of Combangio, Inc. and also served on its Board of Directors. Dr. Cochran also served on the Board of Directors of Nodus Therapeutics, Inc. and as a Member of the Scientific Advisory Board at Aravive Biologics, Inc. Dr. Cochran is a serial innovator and entrepreneur who enjoys mentoring others on technology transfer and life science company formation. Her research and translational interests span protein-based drug discovery and development for applications in oncology, regenerative medicine, and ophthalmology, and the development of new technologies for high-throughput protein analysis and engineering. She has published numerous research papers and is a named inventor on numerous patent applications. Dr. Cochran was inducted as a fellow to the American Institute for Medical and Biological Engineering (AIMBE) and the National Academy of Engineering, the latter for “contributions to biopharmaceutical protein discovery and development, biotechnology entrepreneurship, and leadership in academic bioengineering.” She is the recipient of several prestigious grants including the National Cancer Institute Howard Temin Award, the Martin D. Abeloff Scholar Award, an American Cancer Society Research Scholar Award, and a Sidney Kimmel Scholar Award, and was named a Mallinckrodt Faculty Scholar. She received a B.S. in Biochemistry from the University of Delaware and a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology, where she also completed a postdoctoral fellowship in Biological Engineering. She completed an additional postdoctoral fellowship at the University of Pennsylvania in Biophysics.

Positions